Diagnostic testing company Meridian Bioscience (Nasdaq: VIVO) saw its shares fall as much as 13 percent in early trading Thursday, as the company downwardly revised its full-year earnings outlook. Shares of Meridian, whose tests can help doctors detect c. diff infection symptoms, were hovering around $23.87 in late-morning trading, after closing at $27.32 the prior […]
Diagnostics company Meridian Bioscience (NASDAQ: VIVO) has received U.S. Food and Drug Administration clearance for a new C. difficile test. C. difficile is a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. In recent years, C. difficile infections have become more frequent, more severe and more difficult to treat, […]
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Diagnostics company Meridian Bioscience (NASDAQ: VIVO) has received federal regulatory clearance to begin selling a pediatric version of its C. difficile test. An earlier version of the test, which the company calls the "illumigene," was cleared for commercialization by the FDA in July. However, that clearance didn't apply to children.
Life science diagnostic testing company Meridian Bioscience had a strong 2010 as swine flu fears pushed up demand for its rapid flu tests. But without swine flu, Meridian announced a 32 percent decrease in the diagnostic test maker's first-quarter earnings for fiscal 2011.
Diagnostic test maker Meridian Bioscience Inc. (NASDAQ:VIVO) capped a "disappointing" fiscal 2010 with fourth-quarter profits that fell below Wall Street's expectations and sent its shares tumbling.
Meridian Bioscience Inc. (NASDAQ:VIVO) has obtained a license to begin selling its illumigene C. difficile molecular test in Canada.
Cincinnati, Ohio life sciences company Meridian Bioscience Inc. (NASDAQ: VIVO) has acquired the outstanding capital stock of Bioline Ltd., the London, England-based maker and distributor of molecular biology reagents, for $23.3 million in cash. Meridian Bioscience also said Tuesday its profits fell 24 percent in the fiscal third quarter from a year ago, while sales […]
Diagnostics company Meridian Bioscience Inc. (NASDAQ: VIVO) has received the go-ahead from the Food and Drug Administration to sell its first molecular test — illumigene C. difficile. Over the years the Cincinnati life science company has gotten good at making diagnostic test kits that detect bugs like C. difficile, which is a bacterium that can […]
Meridian Bioscience Inc. (NASDAQ: VIVO) has struck an exclusive, world-wide product development and distribution agreement with an Italian diagnostics company that is likely to open doors to new customers in Eastern Europe and Asia. The agreement with DiaSorin S.p.A. of Vercelli, Italy, is a turnabout for Cincinnati, Ohio, diagnostic kit maker Meridian, said Todd Morrow, […]
Meridian Bioscience has filed an application for federal regulatory approval of a next-generation molecular test that detects a type of bacteria that causes damage to the digestive system. Meridian’s illumigene test is designed to find traces of C. difficile, a bacteria that can cause life-threatening inflammation of the colon and most often affects elderly people […]
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Meridian Bioscience Inc. reported record revenue and net income for its fiscal first quarter, despite increased competition for sales of C. difficile test kits. The Cincinnati company has been working on an answer to growing C. difficile test competition: illumigene.
A bureaucratic snafu helped make the Cleveland Clinic look like it's not as interested as it should be in combating the increasingly deadly intestinal bug know as c.diff.
